ALKS – alkermes plc - ordinary shares (US:NASDAQ)
Stock Stats
News
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
Alkermes (ALKS) had its price target raised by Bank of America Corporation from $34.00 to $36.00. They now have a "neutral" rating on the stock.
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
Alkermes (ALKS) was upgraded by Truist Financial Corporation to "strong-buy".
Form 4 Alkermes plc. For: Apr 11 Filed by: Lurker Nancy
Form 4 Alkermes plc. For: Apr 06 Filed by: Gaffin David Joseph
Form ARS Alkermes plc. For: Dec 31
Form DEFA14A Alkermes plc.
Form DEF 14A Alkermes plc. For: May 20
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.